Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.|
|Authors: ||Jorissen, Winde|
Van Wijmeersch, Bart
Bogie, Jeroen F. J.
Op 't Eijnde, Bert O.
Hendriks, Jerome J. A.
|Issue Date: ||2018|
|Citation: ||INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19(1), p. 1-11 (Art N° 139)|
|Abstract: ||Multiple sclerosis (MS) is an inflammatory auto-immune disease of the central nervous
system (CNS). Serum glucose alterations and impaired glucose tolerance (IGT) are reported in MS
patients, and are commonly associated with the development of cardio-metabolic co-morbidities.
We previously found that a subgroup of MS patients shows alterations in their lipoprotein profile that
are similar to a pre-cardiovascular risk profile. In addition, we showed that a high-intensity exercise
training has a positive effect on IGT in MS patients. In this study, we hypothesize that exercise
training positively influences the lipoprotein profile of MS patients. To this end, we performed a pilot
study and determined the lipoprotein profile before (controls, n = 40; MS patients, n = 41) and after
(n = 41 MS only) 12 weeks of medium-intensity continuous training (MIT, n = 21, ~60% of VO2max)
or high-intensity interval training (HIT, n = 20, ~100–200% of VO2max) using nuclear magnetic
resonance spectroscopy (NMR). Twelve weeks of MIT reduced intermediate-density lipoprotein
particle count ((nmol/L); −43.4%; p < 0.01), low-density lipoprotein cholesterol (LDL-c (mg/dL);
−7.6%; p < 0.05) and VLDL size ((nm); −6.6%; p < 0.05), whereas HIT did not influence the lipoprotein
profile. These results show that MIT partially normalizes lipoprotein alterations in MS patients.
Future studies including larger patient and control groups should determine whether MIT can
reverse other lipoprotein levels and function and if these alterations are related to MS disease
progression and the development of co-morbidities.|
|Notes: ||Hendriks, JJA (reprint author), Hasselt Univ, Sch Life Sci, BIOMED, B-3590 Diepenbeek, Belgium, firstname.lastname@example.org; email@example.com; firstname.lastname@example.org; email@example.com; firstname.lastname@example.org; email@example.com; Alan.Remaley@nih.gov; firstname.lastname@example.org; email@example.com|
|ISI #: ||000424407200190|
|Type: ||Journal Contribution|
|Appears in Collections: ||Research publications|
Files in This Item:
|Published version||507.53 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.